Arlene M. Morris
CEO, Affymax, Inc.
Ms. Morris brings significant expertise in the development of strategic partnerships, marketing and operations to Affymax. She has more than 25 years of management experience from Johnson & Johnson, Scios Inc., Coulter Pharmaceutical, Inc. and most recently Clearview Projects. Ms. Morris joined Affymax from Clearview Projects, where she was the President and CEO. Clearview Projects is an advisory firm that counsels biopharmaceutical and biotechnology companies on strategic transactions. While at Coulter, she completed numerous transactions including the $1 billion merger between Coulter and Corixa and a contractual joint venture with GlaxoSmithKline (GSK) for Bexxar(r) valued in excess of $200 million. Previously, Ms. Morris was the Vice President of Business Development at Scios Inc. where she completed several high-profile transactions including one of the first biotech profit-sharing deals for a late-stage product. From 1977 through 1993, Ms. Morris held various management and executive positions at Johnson & Johnson in sales, marketing, new product development and business development, holding the position of Vice President of Business Development for McNeil Pharmaceutical from 1988 to 1993. She received her B.A. degree in Biology and Chemistry from Carlow College and studied marketing at Western New England College. Ms. Morris also serves on the board of directors of MediciNova, Inc., a specialty pharmaceutical company, Nuon Therapeutics, the Biotechnology Industry Organization (BIO), and the Humane Society of Silicon Valley.